Harmony Biosciences Faces Patent Setback: Analyst Downgrades Stock
Truist analyst downgrades Harmony Biosciences to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat.
Truist analyst downgrades Harmony Biosciences to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat.
Harmony Biosciences’ experimental drug ZYN002 failed its Phase 3 trial for Fragile X syndrome, failing to meet its main goal for improving social avoidance primarily due to a high placebo response.